NCT06754930View on ClinicalTrials.gov

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

February 18, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
DRUG

SHR-1826

SHR-1826 for injection.

DRUG

SHR-1316

SHR-1316 for injection.

DRUG

SHR-9839

SHR-9839 for injection.

DRUG

SHR-8068

SHR-8068 for injection.

DRUG

Ametinib mesylate

Ametinib mesylate.

DRUG

BP-102

BP-102 for injection.

DRUG

Carboplatin

Carboplatin for injection.

Trial Locations (1)

200030

RECRUITING

Shanghai Chest Hospital, Shanghai

All Listed Sponsors
lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY